QualityDipStocks / Health Care · Pharmaceuticals
PTC Therapeutics PTCT
Outside our quality screen, so we don’t track its dips. It’s 32% below its 52-week high.
Outside our quality screen. No fair value estimate for now: its free cash flow is near zero.
Worth knowing
- Net cash = 31% of its market cap
From the data on this page, as of the last close. How we pick these
- Fair value est.
- n/a
- Market Value
- forming
- Off 52-wk high
- −32%
- Risk vs market
- Below marketbeta 0.78
4 bullish · 5 bearish See why
Repriced or dip?
Dip: business intact
The price is 32% below its 52-week high (Jul 9), but the business held up: revenue +39.7%, revenue growth rate +18.3 pts, free cash flow −$226M → $2M, turned positive.
Some numbers held up (revenue +39.7%, revenue growth rate +18.3 pts, free cash flow −$226M → $2M, turned positive), others slipped. The price is 32% below its 52-week high.
The price is 32% below its 52-week high, and the business changed too.
Within 10% of its 52-week high, so there is no dip to judge yet.
The evidence 8 numbers, high vs now
- Revenue, last 12 months$827M → $1.2B (+39.7%)held up
- Revenue growth rate−53.3% → −35.1% a year (+18.3 pts)held up
- Free cash flow, 12 months−$226M → $2M, turned positiveheld up
- Operating margin−7.1% → 12.8% (+19.8 pts)held up
- Shares outstanding+1.2% (more shares, each owns less)held up
- Net cash (cash minus debt)−0.3% of market cap since the highheld up
- Stock vs its sector (Health Care)stock −32%, sector median +4% since Jul 9changed
- Price fall vs business numbersprice −32%, revenue/EPS/FCF median +40% (shown, not scored)
Business numbers as reported at the high (12 months to Mar 31, 2026) vs the latest filing (12 months to Sep 30, 2026). Each measure is scored from −1 (business changed) to +1 (business intact) and weighted: revenue, earnings per share, free cash flow, operating margin, revenue growth rate, share count, net cash and the move vs its sector. 60 or more reads as a dip, 40 or less as a repricing. Analyst estimates are not in our data, so they are not used. How to read it
Data-based read, not advice.
Valuation
What we estimate it's worth, and how it ranks on value vs every stock we cover.
Fair value estimate
No estimate for PTCT: free cash flow is barely positive ($0.02 a share); a DCF says little. We’d rather show nothing than a made-up number.
Risk vs market
How risk vs market is measured
One year of daily returns (Oct 31 to Nov 2, 252 sessions). Beta = how much PTCT moved for each 1% move in the S&P 500 (SPY); 1.0 moves with the market. Volatility is the yearly standard deviation of daily returns. Past behavior, not a forecast.
Moves a bit less than the market, but its own price swings are 3.2× the S&P 500’s (it moves on its own news).
- Beta vs S&P 500
- 0.78
- Volatility
- 41% vs 13% SPY
- Correlation SPY
- 0.24
- Correlation QQQ
- 0.20
How it ranks
Where PTCT stands vs every one of the 1,996 stocks we cover that has the number. Longer bar = better.
Not in the top quarter on any of these 4 measures
- Free cash flow yield0% · free cash flow vs market capLowest 17%of 1,391
- Dividends + buybacks yield0% · cash paid out or used to retire shares, vs market capLowest 1%of 1,836
- Revenue growth, last 12 months−35% · vs the 12 months beforeLowest 1%of 1,814
- Operating margin13% · of sales kept as operating profitTop 48%of 1,288
From SEC filings and our fair value estimate model. A ranking, not advice.
Valuation details
Fundamentals
The business itself: sales, profits, cash and debt, from SEC filings.
Bull vs bear
Rule-based from the data on this page, strongest first. Not advice.
Top bullish points 4 of 5
ProfitabilityOperating margin widened to 50.1% in FY2025 from −46.9% in FY2023 (SEC filings).
GrowthSales compounded 35% a year from FY2022 to FY2025.
Balance sheetNet cash of $1.6B: cash and short-term investments exceed debt (Sep 30, 2026).
Cash returnsShare count down 4.2% in a year.
Top bearish points 5 of 5
GrowthSales fell 35% over the last 12 months vs the 12 months before (SEC filings).
GrowthSales growth slowed to −35% over the last 12 months, from 35% a year over the prior three fiscal years.
ProfitabilityLost $106M over the last 12 months (net income, SEC filings).
Cash returnsFree cash flow fell 100% over the last 12 months vs the 12 months before.
ValuationFree-cash-flow yield is just 0.0%.
All fundamentals
FCF yield 0.0% · Sales −35%
Valuation
- P/E
- n/aloss over the last 12 months
- Price / FCF
- n/an/m: free cash flow near zero
- FCF yield
- 0.0%
- EV / EBITDA
- 16.7×
- Price / sales
- 4.40×
- Price / book
- n/anot reported in its SEC filings
- Market cap
- $5.1Bprice × diluted shares
- Enterprise value
- $3.5B
Growth
- Revenue, 12 months
- $1.2B
- Sales growth, 12 months
- −35.1%vs the 12 months before
- Sales growth, 3 yrs
- +35.3%/yrfrom FY2022
- Diluted EPS, 12 months
- −$1.33
- EPS growth, last FY
- n/afewer than two years of diluted EPS
- Net income, 12 months
- −$106M
- Net income growth
- n/anot reported in its SEC filings
Profitability
- Gross margin
- n/agross profit isn't reported (common for service and financial companies)
- Operating margin
- 12.8%
- Net margin
- −9.2%
- FCF margin
- 0.2%
- Return on equity
- n/anegative shareholder equity
- Return on invested capital
- n/aoperating income, debt, equity or cash not tagged
Balance sheet
- Cash & short-term inv.
- $2.1B
- Total debt
- $536M
- Net cash
- $1.6B
- Debt / equity
- n/adebt or equity not tagged in SEC data
- Interest coverage
- n/ainterest expense not tagged in SEC data
Cash flow & returns
- Free cash flow, 12 months
- $2M
- FCF growth, 12 months
- −100%
- Dividend yield
- 0%
- Payout ratio
- n/anot reported in its SEC filings
- Buybacks, 12 months
- n/anot reported in its SEC filings
- Share count, 1 year
- −4.2%diluted shares vs a year ago
- Stock-based comp
- $89M
Trailing 12 months to Sep 30, 2026; balance sheet at Sep 30, 2026. From PTC Therapeutics’s SEC filings. Sparklines show up to six fiscal years. n/a means we don’t hold that number, with the reason. How each is computed.
The business
FCF $0.0B · Sales +70%
- Free cash flow, 12 months$0.0B
- Gross margin55%
- Operating margin38%
- Return on invested capital56%
- Sales growth (latest quarter vs year-ago quarter)+70%
- Net debt / EBITDA2.6×
Chart & levels
Where the price is vs its key levels and trends.
Key levels
Every level vs today’s $60.88
- 52-wk lowlowest close, 1 year$59.24−2.7%
- PriceMon Nov 2 close$60.88you are here
- 52-wk highhighest close, 1 year$89.55+47.1%
Momentum & 52-week range
RSI 44 · 5 days −0.3%
Signals
Reversal signal setups, the public ledger and the next earnings date.
Setup & signals
No setup armed
No setup armed, so there’s no trigger or stop to track yet. Reversal signal rules only run on companies that pass our quality screen.
PTCT is outside our quality screen
One text when a published rule fires on one of the 332 quality companies we track: the ticker, the price, the stop and a link to the numbers. Nothing else.
Voices & buzz
Who is talking about it, and how it compares with peers.
Who’s talking about it
Notable investors, executives, analysts and public figures on PTC Therapeutics in the last 48 hours. Headlines as published, each linked. Their words, not ours.
No notable mentions in the last 48 hours. Checked Nov 3, 1:01 PM ET.
Compare with peers
Closest in size in Pharmaceuticals
Information only, not investment advice. Fair value estimates and talking points are rule-based model output from public data and can be wrong; stop levels are reference points, not orders. How every number is computed.